| P50 | author | Cara A Timpani | Q86409870 |
| | Joel C. Bornstein | Q46920767 |
| | Kulmira Nurgali | Q50149515 |
| | Rachel M McQuade | Q57051747 |
| | Raquel Abalo | Q60317280 |
| P2093 | author name string | Rhian Stavely | |
| | Vanesa Stojanovska | |
| | Aaron C Petersen | |
| | Emma Rybalka | |
| P2860 | cites work | Exercise training attenuates neuropathic pain and cytokine expression after chronic constriction injury of rat sciatic nerve | Q83640314 |
| | Adjuvant chemotherapy in older patients with stage III colon cancer: an underused lifesaving treatment | Q84292265 |
| | Gastrointestinal dysfunction and enteric neurotoxicity following treatment with anticancer chemotherapeutic agent 5-fluorouracil | Q87774542 |
| | Loss of human Greatwall results in G2 arrest and multiple mitotic defects due to deregulation of the cyclin B-Cdc2/PP2A balance | Q24318937 |
| | Nitric oxide and peroxynitrite in health and disease | Q24645400 |
| | DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer | Q27853235 |
| | Heat shock proteins and cell proliferation in human breast cancer biopsy samples | Q28249702 |
| | A novel and selective poly (ADP-ribose) polymerase inhibitor ameliorates chemotherapy-induced painful neuropathy | Q28484947 |
| | PARP-1 Inhibition Is Neuroprotective in the R6/2 Mouse Model of Huntington's Disease | Q28547107 |
| | Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy | Q28564187 |
| | BGP-15 - a novel poly(ADP-ribose) polymerase inhibitor - protects against nephrotoxicity of cisplatin without compromising its antitumor activity | Q28582227 |
| | The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands | Q28603128 |
| | Dose translation from animal to human studies revisited | Q29618049 |
| | Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress | Q29619552 |
| | Oral and intestinal mucositis — causes and possible treatments | Q33195001 |
| | Iniparib plus chemotherapy in metastatic triple-negative breast cancer | Q33393514 |
| | Clinical pharmacokinetics of oxaliplatin: a critical review | Q33898003 |
| | Animal research: reporting in vivo experiments: the ARRIVE guidelines | Q34116755 |
| | Consequences of intestinal inflammation on the enteric nervous system: neuronal activation induced by inflammatory mediators. | Q34123459 |
| | Oxaliplatin-induced chronic peripheral neurotoxicity: a prospective analysis in patients with colorectal cancer | Q34494728 |
| | Glutamine and heat shock protein expression | Q34554295 |
| | FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic O | Q34565268 |
| | PARP inhibition alleviates diabetes-induced systemic oxidative stress and neural tissue 4-hydroxynonenal adduct accumulation: correlation with peripheral nerve function | Q34851871 |
| | Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice | Q35019148 |
| | The challenges of colorectal cancer survivorship | Q35032967 |
| | Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management | Q35187357 |
| | Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans | Q35361897 |
| | Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy | Q35449249 |
| | Prevention of chemotherapy and radiation toxicity with glutamine. | Q35571238 |
| | Oxaliplatin triggers necrosis as well as apoptosis in gastric cancer SGC-7901 cells | Q35576421 |
| | Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility | Q35584874 |
| | Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? | Q46693516 |
| | PARP inhibitors attenuate chemotherapy-induced painful neuropathy | Q46970236 |
| | Expression of heat shock protein 70 and p53 in human lung cancer | Q47757762 |
| | Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy | Q48133658 |
| | Rectal prolapse in Winnie mice with spontaneous chronic colitis: changes in intrinsic and extrinsic innervation of the rectum. | Q48294063 |
| | Neuroprotective effects of NU1025, a PARP inhibitor in cerebral ischemia are mediated through reduction in NAD depletion and DNA fragmentation. | Q48436198 |
| | Development of colonic motility in the neonatal mouse-studies using spatiotemporal maps | Q48637373 |
| | Hsp70 suppresses apoptosis in sympathetic neurones by preventing the activation of c-Jun. | Q50659448 |
| | Prognostic significance of heat shock proteins HSP70 and HSP90 in endometrial carcinomas. | Q50856443 |
| | Cisplatin-induced gastrointestinal dysmotility is aggravated after chronic administration in the rat. Comparison with pica. | Q51179785 |
| | Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. | Q51741671 |
| | The distribution and chemical coding of intramural neurons supplying the porcine stomach - the study on normal pigs and on animals suffering from swine dysentery. | Q51751780 |
| | BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. | Q54528429 |
| | Enteric neuropathy evoked by repeated cisplatin in the rat | Q57121953 |
| | Protein expression profile of primary human squamous cell lung carcinomas indicative of the incidence of metastases | Q58597966 |
| | Oxaliplatin: mechanism of action and antineoplastic activity | Q60641680 |
| | Pica—A model of nausea? Species differences in response to cisplatin | Q61694390 |
| | Effects of poly(ADP-ribose) polymerase inhibition on dysfunction of non-adrenergic non-cholinergic neurotransmission in gastric fundus in diabetic rats | Q63453452 |
| | Nitric oxide induces oxidative stress and apoptosis in neuronal cells | Q73103710 |
| | BGP-15, a nicotinic amidoxime derivate protecting heart from ischemia reperfusion injury through modulation of poly(ADP-ribose) polymerase | Q73487675 |
| | Chemotherapy-induced peripheral neuropathy | Q77944571 |
| | Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients | Q80092097 |
| | Radiological study of gastrointestinal motor activity after acute cisplatin in the rat. Temporal relationship with pica | Q81522111 |
| | TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer | Q35647212 |
| | Enteric motor and interneuronal circuits controlling motility | Q35738916 |
| | Role of vasoactive intestinal peptide and inflammatory mediators in enteric neuronal plasticity | Q35738968 |
| | Effects of mitochondrial poisons on the neuropathic pain produced by the chemotherapeutic agents, paclitaxel and oxaliplatin | Q35784775 |
| | Heat shock response and insulin-associated neurodegeneration | Q35870561 |
| | Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea | Q36026126 |
| | Poly(ADP-ribose) polymerase inhibition alleviates experimental diabetic sensory neuropathy | Q36431822 |
| | Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. | Q36571464 |
| | Hsp90 as a target for drug development | Q36635195 |
| | Effects of oxaliplatin on mouse myenteric neurons and colonic motility | Q36676211 |
| | The mitochondrial permeability transition in neurologic disease | Q36775895 |
| | Priorities in colorectal cancer research: recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups. | Q36835370 |
| | The role of mitochondrial DNA damage and repair in the resistance of BCR/ABL-expressing cells to tyrosine kinase inhibitors | Q37139171 |
| | Comparison of oxaliplatin- and cisplatin-induced painful peripheral neuropathy in the rat. | Q37341155 |
| | Role of oxidative stress in oxaliplatin-induced enteric neuropathy and colonic dysmotility in mice. | Q37430558 |
| | Oxidative stress and nerve damage: role in chemotherapy induced peripheral neuropathy | Q37541146 |
| | Electrophysiological and morphological changes in colonic myenteric neurons from chemotherapy-treated patients: a pilot study | Q37561412 |
| | The enteric nervous system and neurogastroenterology. | Q37990818 |
| | Platinum-based chemotherapy: gastrointestinal immunomodulation and enteric nervous system toxicity. | Q38287054 |
| | Mitochondria: Inadvertent targets in chemotherapy-induced skeletal muscle toxicity and wasting? | Q38831900 |
| | Disturbances of colonic motility in mouse models of Hirschsprung's disease. | Q40012892 |
| | Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents. | Q40453511 |
| | The mitochondrial permeability transition. | Q40462729 |
| | Oxaliplatin-induced mitochondrial apoptotic response of colon carcinoma cells does not require nuclear DNA. | Q40521489 |
| | Differential, stage-dependent expression of Hsp70, Hsp110 and Bcl-2 in colorectal cancer | Q40587785 |
| | Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications | Q41082338 |
| | Heat shock proteins increase resistance to apoptosis. | Q41226590 |
| | Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. | Q42332476 |
| | Experimental design and analysis and their reporting: new guidance for publication in BJP. | Q42356330 |
| | Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons. | Q42586741 |
| | THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors | Q42660449 |
| | THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes | Q42660454 |
| | THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview | Q42660459 |
| | The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer | Q43230085 |
| | Physical exercise induces excess hsp72 expression and delays the development of hyperalgesia and allodynia in painful diabetic neuropathy rats | Q43689974 |
| | BGP-15, a hydroximic acid derivative, protects against cisplatin- or taxol-induced peripheral neuropathy in rats | Q44494738 |
| | Molecular plasticity of primary nociceptive neurons: relations of the NGF-c-jun system to neurotomy and chronic pain. | Q44552845 |
| | Segmentation induced by intraluminal fatty acid in isolated guinea-pig duodenum and jejunum. | Q44750434 |
| | Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy | Q44775267 |
| | Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study | Q44846367 |
| | Persistent neuropathy after treatment with cisplatin and oxaliplatin | Q46077688 |
| | Analysis of cytotoxicities of platinum compounds | Q46607500 |
| | X-ray analysis of gastrointestinal motility in conscious mice. Effects of morphine and comparison with rats. | Q46651121 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 656-677 | |
| P577 | publication date | 2018-01-11 | |
| P1433 | published in | British Journal of Pharmacology | Q919631 |
| P1476 | title | Oxaliplatin-induced enteric neuronal loss and intestinal dysfunction is prevented by co-treatment with BGP-15 | |
| P478 | volume | 175 | |